It is now well known that Parkinson's disease is associated with a decreased concentration of dopamine within the striatum (Hornykiewicz, 1966) . It is equally well established that the concentration of homovanillic acid, the major catabolic product of dopamine metabolism, is also decreased in the cerebrospinal fluid (CSF) of patients with Parkinson's disease (Johansson and Roos, 1967) . The effectiveness of levodopa therapy in Parkinson's disease has resulted in numerous attempts to understand the neuropharmacological changes involved. A number of investigators have analysed the CSF for the catabolic products of dopamine. It was demonstrated that chronic oral levodopa therapy elevated the CSF homovanillic acid concentration but that the raised level had no quantitative relationship to improvement in the symptoms of Parkinsonism (Weiner, Harrison, and Klawans, 1969; Curzon, Godwin-Austen, Tomlinson, and Kantamaneni, 1970) . Recently there have been several reports concerning homovanillic acid in CSF which have cast doubt on the earlier con- clusion and that have implied that there is a definite correlation between increasing CSF 747 homovanillic acid concentration and improvement in Parkinson's disease (Godwin-Austen, Kantamaneni, and Curzon, 1971; Hinterberger and Andrews, 1972) . It has also been proposed on the basis of the initial cerebrospinal fluid homovanillic acid concentration in patients with Parkinson's disease that it is possible to differentiate two populations of patients: one population that will respond to L-dopa and one population that will not (Jequier and Dufresne, 1972) . The present study was undertaken to determine in a large series of patients whether alterations in CSF homovanillic acid were correlated with improvement in the disease state and to-determine whether there is any prognostic value to the initial concentration of homovanillic acid in the cerebrospinal fluid.
METHODS
Sixty patients with Parkinson's disease were evaluated clinically and given a rating score on the Northwestern disability scale (Canter, de la Torre, and Mier, 1961) . This consists of five separate scales, each of which pertains to one type of activity (walking, dressing, eating and feeding, hygiene, and speech). Each activity is rated from 0 (normal) to 10 (total disability). Before beginning therapy with levodopa a lumbar puncture was performed and the CSF was analysed for homovanillic acid. The patients were started on gradually increasing doses of levodopa until a satisfactory result was obtained, which initially was in the range of 3-4 g daily. At the end of two to four weeks of observation a second clinical interview with assessment of the Northwestern University scale rating was obtained. A second lumbar puncture was performed and the CSF again analysed for homovanillic acid.
The samples of CSF were simultaneously analysed by the fluorometric method of Anden, Roos, and Werdinius (1963) . A modification in this method was the use of ethylacetate (Sharman, 1963) HVA (ng/mI.) HVA (nq/ml.) response was 18-5 ng/ml., while in those 43 patients in whom the response to levodopa was less than 400 the average CSF fluid homovanillic acid was 15-4 ng/ml. There was no statistical difference in these values within the method of analysis employed for CSF homovanillic acid. group.bmj.com on April 15, 2017 -Published by http://jnnp.bmj.com/ Downloaded from 10-5 ng/ml. was lower than the average concentration of 18-5 ng/ml. for patients who improved more than 4000. There is no significant difference between these two values.
Table 2 also indicates that, despite the fact that there was little or no improvement in this group's disability scores, there was always an increase in the concentration of CSF homovanillic acid provided the patients were given longterm levodopa therapy. Table 3 shows the average CSF homovanillic acid concentration before and during treatment with levodopa for all groups of patients with Parkinsonism.
In Fig. 1 the initial CSF homovanillic acid concentration is correlated with the initial raw score on the Northwestern disability scale. Although it can be seen that there is no direct linear relationship in these two variables, there is certainly a suggestion of a relationship. In a crude fashion it appears that the higher the initial disability of the patient the lower the initial CSF homovanillic acid concentration. It is obvious that this is a generalization and that for a given patient this relationship might not be at all true. Figure 2 represents the relationship between percent improvement on the disability scale rating and CSF homovanillic acid concentration during L-dopa therapy. There is no relationship between these two variables.
DISCUSSION
The finding of a possible relationship between low levels of cerebrospinal fluid homovanillic acid in the pretreatment stage and increased disability rating is of interest. Homovanillic acid is the final product of dopamine catabolism and the major catabolic product of dopamine. Only small amounts of homovanillic acid penetrate from the plasma into the spinal fluid, and the spinal fluid concentration of homovanillic acid is felt to reflect the turnover of dopamine within the brain (Bartholini, Pletscher, and Tissot, 1966) . The brains of all patients who have died with Parkinson's disease, which have had the appropriate chemical analyses performed, have revealed decreased striatal dopamine (Ehringer and Hornykiewicz, 1960) . The pathology of Parkinson's disease is a degenerative process involving the dopaminergic-rich nigrostriatal neuronal system. It might be reasonable, therefore, to assume that in Parkinson's disease as the degenerative process continues the striatal dopamine concentration falls. When the striatal dopamine concentration decreases, the turnover of dopamine is decreased and subsequently the concentration of CSF homovanillic acid is decreased. In a large series of patients, Rinne and Sonninen (1972) have also found a similar negative correlation between lumbar CSF homovanillic acid level and severity of disease and disability. Our results and those of Rinne and Sonninen suggest that lower CSF homovanillic acid levels are related to greater degrees of disability from Parkinsonism, probably as a reflection of decreased turnover of striatal dopamine.
There was no significant correlation between lumbar CSF homovanillic acid and age in our patients. This is similar to the results of Guldberg, Ashcroft, and Turner (1969) and Rinne and Sonninen (1972) . Bowers (1972) Table 2 all eight patients with little or no response to levodopa are seen to have increased CSF homovanillic acid. This lack of correlation between lack of clinical response and elevation of CSF homovanillic acid has been noted previously (Weiner et al., 1969; Curzon et al., 1970) . In controlled circumstances, where it is certain that the patient is receiving and taking the medication, the only time we have observed the failure of CSF homovanillic acid to increase while on levodopa was in a single patient who inadvertently was receiving vitamin B6 simultaneously (Klawans, 1971a) . After vitamin B6 was discontinued the patient had a good clinical response to levodopa and an elevation in CSF homovanillic acid level.
The failure of CSF homovanillic acid to increase while on long-term levodopa therapy is difficult to understand. The possibility that the patient is inadvertently receiving vitamin B6 or that he is not really taking his medication must always be considered. It is now known that nowhere near all of the homovanillic acid found in the cerebrospinal fluid after levodopa is related to dopamine metabolism. A significant percentage of the measurable homovanillic acid is actually formed within the walls of the cerebral capillaries from circulating L-dopa (Falck et al., 1962) . Levodopa therapy should result in elevated circulating levodopa levels and increased CSF homovanillic acid levels in all patients unless there is increased peripheral metabolism, due perhaps to excess vitamin B6 (Klawans, 1971a) or possibly poor absorption of levodopa.
It is our contention that the CSF homovanillic acid concentration should not be regarded as a reliable indication of whether or not to continue therapy in the poorly responding patient. There is no correlation between CSF homovanillic acid concentration, chronic levodopa therapy, and clinical status. Three patients (A16, B16, and B33) had an increase in CSF homovanillic acid of 10 ng/ml. or less. The increase in CSF homovanillic acid in these three patients respectively was 9, 9, and 10 ng/ml. The percentage improvement in these patients respectively was 40, 16, and 38%. This is an average improvement of 28%, which is not significantly different from the average improvement of all 60 patients (31.5%). Clinical experience with chronic levodopa therapy has demonstrated that in some patients three to six months of therapy is required before significant improvement is seen.
Another recent suggestion by Jequier and Dufresne (1972) that patients with Parkinsonism can be divided into two prognostic populations based on the initial CSF homovanillic acid concentration needs further investigation. These authors suggest that there is one population of patients with low CSF homovanillic acid who respond better to levodopa treatment and that a second group of patients with normal CSF homovanillic acid do not respond to levodopa. We have found no evidence to support these postulates. In 17 patients whose initial response was greater than 4000 improvement while on levodopa therapy, the average CSF homovanillic acid was 18-5 ng/ml., while in 43 patients with less than 4000 improvement while on levodopa therapy the average CSF homovanillic acid was 15-4 ng/ml. The five patients with the highest levels of homovanillic acid were also examined closely in this regard. If there is a subgroup of patients with Parkinsonism with normal or near normal CSF homovanillic acid levels who do not respond to levodopa, they should be found among these patients. The five patients B28, B 13, A5, B5, and A3 had homovanillic acid levels respectively of 64, 60, 56, 47, and 46 ng/ml. The mean CSF fluid homovanillic acid of these five patients was 54-6 nglml., as opposed to 16-3 ng/ml. for the entire group and 66 ng/ml. for normal individuals (Klawans, 1971b (Guldberg, Ashcroft, Turner, and Hanieh, 1968) as well as in normal dogs (Guldberg et al., 1966 
